Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Linde (LIN)

NASDAQ: LIN · Specialty Chemicals · Woking Surrey, X0

Our rating: Neutral

Neutral reaffirmed at $514.24, moderate conviction, October 30, 2026.

Breaks if: The Neutral call turns Cautious if net income margin falls below 18% for two consecutive quarterly prints — that would signal pricing power or cost discipline is genuinely deteriorating, and 35x earnings would be plainly indefensible. It turns Positive if annual revenue growth re-accelerates above 6% within the next four quarters while reported free cash flow climbs above $6.0B, indicating the clean-energy pipeline is lifting the base business in reported numbers rather than remaining a long-dated option.

Key figures

Market value$230.8B
Revenue, last 12 months$36.2B
Net income, last 12 months$7.0B
Free cash flow, last 12 months$5.1B
Price to earnings32.9×
Free cash flow yield2.2%
Dividend yield1.3%
Operating margin25.3%
Return on equity18.0%
Beta to the S&P 5000.44
Volatility, annualized18.0%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$9.4B9.2%$3.66$1.8B
June 30, 2026$9.3B9.3%$4.15$833M
March 31, 2026$8.8B8.2%$3.98$898M
December 31, 2025$8.8B5.8%$3.27$1.6B
September 30, 2025$8.6B3.1%$4.09$1.7B
June 30, 2025$8.5B2.8%$3.73$954M
March 31, 2025$8.1B0.1%$3.51$891M
December 31, 2024$8.3B−0.2%$3.60$1.6B

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

14 ledger entries and 26 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.